Jim Woodgett, Ph.D. (Dundee U) moved to Canada in 1992 to work at the Ontario Cancer Institute. His research is focused on signalling mechanisms that underscore malignant growth, degenerative diseases, cell fate determination and diabetes. From 1995-2005, he was an International Scholar of the Howard Hughes Medical Institute and in 1997 was appointed Head of the Division of Experimental Therapeutics. A full professor in the department of medical biophysics at the University of Toronto, he has been an MRC Scientist and CIHR Senior Scientist and is known for his work on a class of proteins that regulate cellular processes, termed protein kinases. In 2005 he was appointed Director of the Samuel Lunenfeld Research Institute at Mount Sinai Hospital (now called the Lunenfeld-Tanenbaum Research Institute). He has served as Chair and member of several CIHR and other funding agency panels around the world and is an active proponent of highest quality peer review.
Abstracts this author is presenting: